Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 18.3% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 18.3% during trading on Wednesday . The stock traded as high as $10.37 and last traded at $9.23. Approximately 897,286 shares traded hands during mid-day trading, an increase of 75% from the average daily volume of 513,853 shares. The stock had previously closed at $7.80.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The company’s 50 day simple moving average is $21.65 and its 200-day simple moving average is $21.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $24.33 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals in the fourth quarter valued at $72,000. Two Sigma Investments LP acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $66,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth approximately $162,000. Jane Street Group LLC grew its holdings in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth approximately $526,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.